TFS Capital’s Cidara Therapeutics CDTX Stock Holding History

TFS Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,051	Closed	-$217K	–	772
2016 Q2	$217K	Buy	+1,051	New	+$254K	0.04%	701

Other funds holding CDTX

Fidelity Investments

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

TFS Capital's CDTX Position: Q3 2016 in Review

TFS Capital sold out of Cidara Therapeutics (CDTX) in Q3 2016, closing a stake of 1,051 shares — an estimated $217K sold.

TFS Capital first reported a position in CDTX in Q2 2016 and held it in 1 quarter. The position peaked at $217K in Q2 2016. 51 funds tracked by Wall St. Rank hold CDTX as of Q3 2016.

TFS Capital reported no remaining Cidara Therapeutics position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 1,051 Cidara Therapeutics shares in Q3 2016, an estimated $217K.
TFS Capital first reported a position in Cidara Therapeutics in Q2 2016 and held it in 1 quarter.
TFS Capital's Cidara Therapeutics position peaked at $217K in Q2 2016.
51 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.